var data={"title":"Capreomycin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Capreomycin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5805?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=capreomycin-drug-information\" class=\"drug drug_general\">see &quot;Capreomycin: Drug information&quot;</a> and <a href=\"topic.htm?path=capreomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Capreomycin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708654\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of capreomycin in patients with renal insufficiency must be undertaken with great caution, and the risk of additional renal injury should be weighed against the benefits derived from therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because other parenteral antituberculosis agents (streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on renal function, simultaneous administration of these agents with capreomycin is not recommended. Use with nonantituberculosis drugs (polymyxin A sulfate, colistin sulfate, amikacin, gentamicin, tobramycin, vancomycin, kanamycin, and neomycin) having nephrotoxic potential should be undertaken only with great caution.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Auditory impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of capreomycin in patients with preexisting auditory impairment must be undertaken with great caution, and the risk of additional cranial nerve VIII impairment should be weighed against the benefits derived from therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because other parenteral antituberculosis agents (streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on cranial nerve VIII, simultaneous administration of these agents with capreomycin is not recommended. Use with nonantituberculosis drugs (polymyxin A sulfate, colistin sulfate, amikacin, gentamicin, tobramycin, vancomycin, kanamycin, and neomycin) having ototoxic potential should be undertaken only with great caution.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The safety of the use capreomycin in pregnancy has not been determined.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pediatric patients:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Safety and effectiveness in pediatric patients have not been established.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145236\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Capastat Sulfate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003476\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antitubercular Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003503\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=capreomycin-drug-information\" class=\"drug drug_general\">see &quot;Capreomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Active t<b>uberculosis infection; treatment multidrug resistant (MDR) (second-line therapy):</b></b> Limited data available: <b>Note:</b> Always use as part of a multidrug regimen. Any regimens using less than once daily dosing should administer dosing as directly observed therapy (DOT). Treatment regimens for MDR TB are variable depending upon sensitivity and clinical response. Capreomycin frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines for detailed information (ATS/CDC/IDSA [Nahid 2016]; Schaaf 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary pulmonary disease:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Once-daily therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years, weighing &le;40 kg: <b>Note</b>: Suggested expert dosing range is large and variable (Schaaf 2015): IM, IV: 15 to 30 mg/kg/dose once daily; some experts recommend an initial dose range of 15 to 20 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b>; monitor serum concentrations (ATS/CDC/IDSA [Nahid 2016]; DHHS [pediatric] 2013; Schaaf 2015; Seddon 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: IM, IV: 15 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b>; monitor serum concentrations (ATS/CDC/IDSA [Nahid 2016]; HHS [adult] 2016; Seddon 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Three-times weekly DOT:</i>Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: IM, IV: 25 mg/kg/dose three times weekly; maximum dose: 1,000 mg/dose (ATS/CDC/IDSA [Nahid 2016]</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Twice-weekly DOT:</i> Infants, Children, and Adolescents &lt;15 years, weighing &le;40 kg: IM, IV: 25 to 30 mg/kg/dose twice weekly; maximum dose: 1,000 mg/dose (ATS/CDC/IDSA [Nahid 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis (independent of HIV-status): Infants, Children, and Adolescents: Suggested expert dosing range is large and variable (Schaaf 2015): IM, IV: 15 to 30 mg/kg/dose once daily; some experts recommend an initial range of 15 to 20 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b>; monitor serum concentrations (ATS/CDC/IDSA [Nahid 2016]; DHHS [pediatric] 2013; <i>Red Book</i> [AAP 2015]; Schaaf 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Tuberculosis:</b> IM, IV: 1,000 mg once daily (maximum dose: 20 mg/kg/dose) for 60 to 120 days, followed by 1,000 mg 2 to 3 times/week <b>or</b> 15 mg/kg/day (maximum: 1,000 mg/dose) for 2 to 4 months, followed by 15 mg/kg (maximum: 1,000 mg/dose) 2 to 3 times/week (CDC 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Maximum single dose: 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 110 mL/minute: Administer 13.9 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 100 mL/minute: Administer 12.7 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 80 mL/minute: Administer 10.4 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 60 mL/minute: Administer 8.2 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 mL/minute: Administer 7 mg/kg every 24 hours <b>or</b> 14 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 mL/minute: Administer 5.9 mg/kg every 24 hours <b>or</b> 11.7 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 mL/minute: Administer 4.7 mg/kg every 24 hours <b>or</b> 9.5 mg/kg every 48 hours <b>or</b> 14.2 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 mL/minute: Administer 3.6 mg/kg every 24 hours <b>or</b> 7.2 mg/kg every 48 hours <b>or</b> 10.7 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 mL/minute: Administer 2.4 mg/kg every 24 hours <b>or</b> 4.9 mg/kg every 48 hours <b>or</b> 7.3 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 0 mL/minute: Administer 1.3 mg/kg every 24 hours <b>or</b> 2.6 mg/kg every 48 hours <b>or</b> 3.9 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following guidelines may also be used:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CDC</i> 2003:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute and/or hemodialysis: 12 to 15 mg/kg (maximum dose: 1,000 mg/dose) 2 to 3 days per week (<b>NOT</b> daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Aronoff</i> 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;10 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: 1,000 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer dose after hemodialysis only</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 5 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; some suggest that no extra precautions are needed (CDC 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145219\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capastat Sulfate: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145204\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003508\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer over 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer by deep IM injection into large muscle mass </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145233\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following reconstitution, may store under refrigeration for up to 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003477\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of pulmonary tuberculosis (TB) in conjunction with at least one other antituberculosis agent when primary anti-TB agents are ineffective (drug-resistant) or patient does not tolerate or resistant tubercle bacilli present (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145264\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Capastat may be confused with Cepastat</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145262\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Nephrotoxicity (increased blood urea nitrogen) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic: Eosinophilia (dose-related, mild) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Hepatic insufficiency (decreased sulfobromophthalein excretion), hypersensitivity (includes fever, maculopapular rash, urticaria), hypocalcemia, hypokalemia, hypomagnesemia, increased serum creatinine, injection site reaction (includes abscess at injection site, bleeding at injection site, induration at injection site, and pain at injection site), leukocytosis, leukopenia, nephritis (toxic), renal tubular necrosis, thrombocytopenia (rare), tinnitus, urine sedimentation abnormality, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145226\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to capreomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145208\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte imbalance: Hypocalcemia, hypokalemia, and hypomagnesemia have been reported with use. Monitor electrolytes periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: May cause nephrotoxicity, including tubular necrosis, increased BUN or serum creatinine, and abnormal urinary sediment; slight elevations in BUN and serum creatinine with urinary RBCs, WBCs, and casts have been observed with prolonged treatment. Monitor renal function at baseline and periodically during treatment. A BUN &gt;30 mg/dL or other evidence of decreasing renal function should prompt clinical evaluation and dosage adjustment or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ototoxicity: May cause impairment of cranial nerve VIII, which may be irreversible; perform audiometric assessment and assessment of vestibular function prior to initiation and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergies: Use with caution in patients who demonstrate some form of allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Auditory impairment:<b> [US Boxed Warning]: Use in patients with preexisting auditory impairment must be undertaken with great caution, and the risk of additional cranial nerve VIII impairment should be weighed against the benefits to be derived from therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment:<b> [US Boxed Warning]: Use in patients with renal impairment must be undertaken with great caution, and the risk of additional renal injury should be weighed against the benefits to be derived from therapy.</b> Dosage reductions are recommended for known or suspected renal impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drugs with ototoxic or nephrotoxic potential: <b>[US Boxed Warning]: Use with nonantituberculous drugs (eg, polymyxin A sulfate, colistin sulfate, gentamicin, tobramycin, vancomycin, neomycin) having ototoxic or nephrotoxic potential should be undertaken only with great caution. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parenteral antituberculous agents: <b>[US Boxed Warning]: Because other parenteral antituberculous agents (eg, streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on cranial nerve VIII and renal function, simultaneous administration of these agents with capreomycin is not recommended.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: <b>[US Boxed Warning]: Safety has not been established in pediatric patients.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[US Boxed Warning]: Safety has not been established in pregnant women.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855278\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause renal injury including tubular necrosis, elevated BUN or serum creatinine, and abnormal urinary sediment; BUN elevation and abnormal urinary sediment are associated with prolonged therapy and the clinical significance of these findings is not fully established. Proteinuria frequently reported; electrolyte disturbances (hypokalemia, hypomagnesemia, and hypocalcemia) may result from renal injury (CDC, 2003). Discontinuation of therapy due to renal toxicity has been reported in 20% to 25% of patients (CDC, 2003). Monitor renal function; urinalysis and electrolytes at baseline and periodically (monthly) throughout therapy (CDC, 2003; Seddon, 2012). May cause hearing loss; some cases may be irreversible. Tinnitus and vertigo have also been reported; more common in elderly patients and patients with preexisting renal impairment. In pediatric patients treated for multidrug-resistant TB, the reported incidence of hearing loss is variable (7% to 24%) with regimens that included either capreomycin or an aminoglycoside; the majority of children received amikacin compared to capreomycin; specific incidence with capreomycin not determined (Drobac, 2006; Seddon, 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298954\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145213\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91300&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Capreomycin may enhance the neuromuscular-blocking effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Capreomycin may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Capreomycin may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Capreomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: Capreomycin may enhance the neuromuscular-blocking effect of Polymyxin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145215\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145228\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been reported in animal reproduction studies. <b>[US Boxed Warning]: Safety has not been established in pregnant women</b>; avoid use during pregnancy because of the risk of fetal nephrotoxicity and congenital hearing loss (MMWR 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003511\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients: Audiometric measurements and vestibular function (baseline, periodically while on therapy, and discontinuation of therapy); renal function (baseline, periodically while on therapy, and following discontinuation of therapy); baseline and frequent assessment of serum electrolytes (including calcium, magnesium, and potassium), liver function tests, growth parameters (ATS/CDC/IDSA [Nahid 2016]; Schaaf 2015; Seddon 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Audiometric measurements and vestibular function at baseline and during therapy; renal function at baseline and weekly during therapy; frequent assessment of serum electrolytes (including calcium, magnesium, and potassium), liver function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49909896\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Tuberculosis treatment: Pediatric patients: Although exact pharmacokinetic/dynamic aminoglycoside targets are unknown for <i>M. Tuberculosis</i>; experts suggest peak values (Cmax): 35 to 45 mcg/mL for once-daily therapy; and for twice-weekly: 65 to 80 mcg/mL (Schaaf 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145207\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Capreomycin is a cyclic polypeptide antimicrobial. It is administered as a mixture of capreomycin IA and capreomycin IB. The mechanism of action of capreomycin is not well understood. Mycobacterial species that have become resistant to other agents are usually still sensitive to the action of capreomycin. However, significant cross-resistance with viomycin, kanamycin, and neomycin occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145225\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Not absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: CrCl 100 to 110 mL/minute: 5 to 6 hours; CrCl 50 to 80 mL/minute: 7 to 10 hours; CrCl 20 to 40 mL/minute: 12 to 20 hours; CrCl 10 mL/minute: 29 hours; CrCl 0 mL/minute: 55 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (52% unchanged within 12 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323040\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Capastat Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $258.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145229\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Capacin (KR);</li>\n      <li>Capastat (AT, AU, CZ, ES, GR, IE, NZ, PL, RU);</li>\n      <li>Kapocin (ET, IN, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Treatment of Tuberculosis,&quot; <i>MMWR Recomm Rep</i>, 2003, 52(RR-11):1-77. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-pediatric-drug-information/abstract-text/12836625[/pubmed\" target=\"_blank\" id=\"12836625[\">12836625[</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis.<i> Pediatrics</i>. 2006;117(6): 2022-2029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-pediatric-drug-information/abstract-text/16740844/pubmed\" target=\"_blank\" id=\"16740844\">16740844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2016. Available at <a href=\"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-pediatric-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaaf HS, Garcia-Prats AJ, Donald PR. Antituberculosis drugs in children. <i>Clin Pharmacol Ther</i>. 2015;98(3):252-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-pediatric-drug-information/abstract-text/26095192/pubmed\" target=\"_blank\" id=\"26095192\">26095192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis- practice-based recommendations. <i>Am J Respir Crit Care Med</i>. 2012;186:953-964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-pediatric-drug-information/abstract-text/22983960/pubmed\" target=\"_blank\" id=\"22983960\">22983960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multi-drug resistant tuberculosis. <i>J Infect</i>. 2013;66:320-3299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-pediatric-drug-information/abstract-text/22960077/pubmed\" target=\"_blank\" id=\"22960077\">22960077</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91300 Version 45.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708654\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F145236\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1003476\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1003503\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F145219\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F145204\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1003508\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F145233\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1003477\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F145264\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F145262\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F145226\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F145208\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855278\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298954\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F145213\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F145215\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F145228\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1003511\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F49909896\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F145207\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F145225\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323040\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F145229\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/91300|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=capreomycin-drug-information\" class=\"drug drug_general\">Capreomycin: Drug information</a></li><li><a href=\"topic.htm?path=capreomycin-patient-drug-information\" class=\"drug drug_patient\">Capreomycin: Patient drug information</a></li></ul></div></div>","javascript":null}